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OBJECTIVE Spinal cord stimulation (SCS) at 10 kHz (10-kHz SCS) is a safe and effective therapy for treatment of
chronic low-back pain. However, it is unclear from existing evidence whether these findings can be generalized to
patients with chronic back pain that is refractory to conventional medical management (CMM) and who have no history
of spine surgery and are not acceptable candidates for spine surgery. The authors have termed this condition “nonsurgical refractory back pain” (NSRBP) and conducted a multicenter, randomized controlled trial to compare CMM with and
without 10-kHz SCS in this population.
METHODS Patients with NSRBP, as defined above and with a spine surgeon consultation required for confirmation,
were randomized 1:1 to patients undergoing CMM with and without 10-kHz SCS. CMM included nonsurgical treatment
for back pain, according to physicians’ best practices and clinical guidelines. Primary and secondary endpoints included
the responder rate (≥ 50% pain relief), disability (Oswestry Disability Index [ODI]), global impression of change, quality
of life (EQ-5D-5L), and change in daily opioid use and were analyzed 3 and 6 months after randomization. The protocol
allowed for an optional crossover at 6 months for both arms, with observational follow-up over 12 months.
RESULTS In total, 159 patients were randomized; 76 received CMM, and 69 (83.1%) of the 83 patients who were
assigned to the 10-kHz SCS group received a permanent implant. At the 3-month follow-up, 80.9% of patients who
received stimulation and 1.3% of those who received CMM were found to be study responders (primary outcome, ≥ 50%
pain relief; p < 0.001). There was also a significant difference between the treatment groups in all secondary outcomes
at 6 months (p < 0.001). In the 10-kHz SCS arm, outcomes were sustained, including a mean 10-cm visual analog scale
score of 2.1 ± 2.3 and 2.1 ± 2.2 and mean ODI score of 24.1 ± 16.1 and 24.0 ± 17.0 at 6 and 12 months, respectively (p
= 0.9). In the CMM arm, 74.7% (56/75) of patients met the criteria for crossover and received an implant. The crossover

ABBREVIATIONS AE = adverse event; CLBP = chronic low-back pain; CMM = conventional medical management; EQ-5D-5L = EQ-5D 5-level; FBSS = failed back surgery
syndrome; IPG = implantable pulse generator; ITT = intention to treat; MCID = minimal clinically important difference; NSRBP = nonsurgical refractory back pain; ODI =
Oswestry Disability Index; PGIC = Patient-Reported Global Impression of Change; PP = per protocol; RCT = randomized controlled trial; SAE = serious AE; VAS = visual
analog scale; 10-kHz SCS = spinal cord stimulation at 10 kHz.
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arm obtained a 78.2% responder rate 6 months postimplantation. Five serious adverse events occurred (procedurerelated, of 125 total permanent implants), all of which resolved without sequelae.
CONCLUSIONS The study results, which included follow-up over 12 months, provide important insights into the durability of 10-kHz SCS therapy with respect to chronic refractory back pain, physical function, quality of life, and opioid use,
informing the current clinical practice for pain management in patients with NSRBP.
Clinical trial registration no.: NCT03680846 (clinicaltrials.gov)
https://thejns.org/doi/abs/10.3171/2021.12.SPINE211301

C

KEYWORDS nonsurgical refractory back pain; pain management; spinal cord stimulation; low-back pain; high-frequency;
10-kHz SCS; lumbar

low-back pain (CLBP) is a common condition that affects an estimated 13.1% of the US
population and is associated with higher levels of
medical comorbidities, increased healthcare costs, and
lost productivity.1,2 According to current clinical guidelines, conventional medical management (CMM) for
CLBP includes analgesic medications, physical therapy,
nerve blocks, epidural steroid injections, radiofrequency
ablation, and other therapies.3–6 We use the terminology
“nonsurgical refractory back pain” (NSRBP) to describe
patients with chronic refractory back pain that does not respond to CMM and who have no history of spine surgery
and are not acceptable candidates for surgery after evaluation by a spine surgeon. This term was first introduced in a
publication by Patel el al.7 There is an unmet need for safe
and effective nonpharmacological therapy for NSRBP,8 as
currently there are few effective treatment options.9
Although evidence for the efficacy of spinal cord stimulation at 10 kHz (10-kHz SCS) in refractory CLBP is now
substantial and of high quality, most patients included in
these studies had a history of back surgery, and most were
diagnosed with failed back surgery syndrome (FBSS).10–13
“Failed back surgery syndrome” is an imprecise term generally understood to identify patients who have had back
surgery at some point in the past and who have persistent
back pain at the present time. While efforts to define more
useful diagnosis-related identifiers are underway,14 the
FBSS term is used for consistency with referenced studies.
A subanalysis of surgery-naive patients in the SENZA–
randomized controlled trial (RCT) and SENZA-EU trials
found efficacy results comparable with those of the full
study cohort,15 and a single-center, prospective, proof-ofconcept study evaluating 10-kHz SCS treatment using a
narrower definition of NSRBP showed profound and durable back and leg pain and functional capacity improvements (at the 3-year follow-up).16,17
Despite their supportive nature, these previous studies
and analyses included only small numbers of patients with
NSRBP, and additional high-quality clinical evidence is
needed regarding both the efficacy and cost-effectiveness
of treatment with 10-kHz SCS in these patients. The current multicenter RCT was designed to compare treatment
via 10-kHz SCS and CMM with CMM alone.7 The results
of this study, including the primary and secondary endpoints and 12-month follow-up, are presented herein.
hronic

Methods

The design of this multicenter RCT has been described

previously.7 Patients for whom CMM had failed and had
not undergone previous lumbar spine surgery were included after providing consent. Patients went on to randomization if they met all inclusion and exclusion criteria
(Supplemental Table 1), with the main inclusion criteria
being a diagnosis of chronic, axial, low-back pain with
a neuropathic component and no previous spine surgery.
In addition, each patient underwent a consultation with a
spine surgeon, whereby they were deemed to be inappropriate candidates for spine surgery.
After meeting inclusion criteria, patients provided written informed consent for randomization and the potential
for crossover. In the prespecified statistical plan, up to 216
patients were allowed to be randomized 1:1 to receive either CMM alone or 10-kHz SCS in addition to CMM. The
randomization used permuted block sizes at each clinical
site to help maintain balance in allocation. Randomization
assignments were computer generated with a code provided by an independent statistician and allocated via the
electronic data capture system.
The trial protocol7 and reporting followed CONSORT
guidelines18 and included outcomes were concordant with
the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidelines.19 The
trial was registered at ClinicalTrials.gov (registration no.
NCT03680846) prior to patient enrollment. The protocol
and informed consent were approved by the Western Institutional Review Board and local site IRBs, as required.
Collection of patient-reported outcomes and other data in
both study arms were performed by clinic-employed personnel. Sponsor involvement of patient management was
limited to technical recommendations and programming,
as supervised by the investigator.
Treatment Groups
Patients randomized to 10-kHz SCS received a trial
stimulation lasting up to 14 days, using 2 percutaneous
leads with 8 contacts each, placed in the epidural space
with final position spanning T8–11 fluoroscopic vertebral
height. Paresthesia-independent stimulation was delivered
at 10 kHz with a pulse width of 30 µsec, and the current
amplitude was adjusted to maximize pain relief. While
low-frequency SCS is thought to achieve pain relief by requiring activation of Aβ fibers in the dorsal column, generating paresthesia and indirectly affecting pain signaling,
recent research has suggested that paresthesia-free pain
relief obtained with 10-kHz SCS is achieved by inhibiting
pain processing more directly in the spinal dorsal horn.20
A successful SCS trial, which was defined as ≥ 50% pain
J Neurosurg Spine Volume 37 • August 2022
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relief, was required for patients to be eligible for permanent implantation of the 10-kHz SCS device (Senza, Nevro Corp.).
Patients randomized to the CMM treatment group continued to receive the best standard of care as determined
for each individual patient by the study investigator. Although not strictly prescribed, CMM was required to be
generally consistent with clinical guidelines developed
by the American College of Physicians and the American
Pain Society, as well as the interventional pain management guidelines developed by the American Society of
Interventional Pain Physicians.6,21
Follow-up visits with assessments were completed at 1,
3, 6, 9, and 12 months after randomization, with optional
crossover available to patients in both arms after completing 6 months in the study.7 Those patients opting to
crossover at 6 months were required to meet the following
criteria: < 50% pain relief from baseline, dissatisfaction
with treatment, and investigator approval of medical appropriateness. The flow of patients through the study from
baseline assessment through 24 months of follow-up is
shown in Supplemental Fig. 1.
Study Flow
Pain intensity and pain relief were measured using a
10-cm visual analog scale (VAS). Pain responders were
defined as those patients who reported pain relief ≥ 50%.
This threshold has been used as the efficacy standard in
most previous studies of SCS, including SENZA-RCT,
SENZA-EU, and the pilot study conducted in patients
with NSRBP.10,11,17 Disability was assessed with the Oswestry Disability Index (ODI),22,23 and we defined ODI
responders as patients who had an improvement in ODI
scores of ≥ 10 points, the minimal clinically important
difference (MCID) for this validated measure.24,25 The
7-point Patient-Reported Global Impression of Change
(PGIC) was used to quantify the perception of functional
change in response to study treatment.26 Patient quality of
life was evaluated using the EQ-5D 5-level (EQ-5D-5L)
instrument score, which assesses changes in health-related
quality of life along 5 dimensions, including mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression.27 The MCID for the EQ-5D-5L varies depending on
the patient population and disease state and is estimated to
range from 0.037 to 0.069.28 We used the upper end of this
range, 0.069, as the MCID when analyzing the results of
this study. Finally, daily opioid use was recorded in patient
diaries by the subset of patients who entered the study on a
regimen of prescribed opioids. These data were converted
to the total daily milligram morphine equivalent to determine if opioid analgesic dosages changed in response to
the study treatment.
The primary endpoint of this study was the responder
rate (≥ 50% pain relief) at 3 months. There were 5 prespecified secondary endpoints that were tested hierarchically
and that compared the following between the treatment
and control groups at 6 months: 1) proportion of patients
with a ≥ 10-point decrease in ODI score from baseline,
2) percentage change from baseline in back pain intensity
(as assessed by the VAS-back), 3) proportion of patients
reporting “better” or “a great deal better” on the PGIC,
190

4) mean change from baseline in the EQ-5D-5L, and 5)
mean change in opioid medication usage.
Adverse events (AEs) were assessed at all visits, including follow-up visits and unscheduled visits, and any serious or treatment-related AEs observed by investigators
or reported by patients were recorded. All serious AEs
(SAEs) were reviewed by the principal investigator of the
site in accordance with medical device reporting requirements.
As an additional safety outcome, a neurological assessment was performed at baseline and at 3-, 6-, and
12-month follow-ups, following the standard-of-care procedure at each investigator’s practice. Neurological status
included motor, sensory, and reflex functions, which were
characterized as improved, maintained, or a deficit as
compared with the baseline status.
Analysis
The assumptions resulting in an estimated sample size
of 216 randomized patients were presented previously.7 A
single prespecified interim analysis was triggered when
40% of the planned study population reached the 3-month
primary endpoint. The objective of the interim analysis
was to assess the prespecified statistical assumptions of
the sample size and determine if it was necessary to increase the sample size, stop the study for futility, or discontinue enrollment for already sufficient power.
The prespecified interim analysis indicated that the
sample size was sufficient to show superiority of treatment for the primary endpoint; therefore, enrollment was
stopped at 211 patients.
The intention-to-treat (ITT) population was defined as
all randomized patients, and the per protocol (PP) population was defined as including only those patients (n = 68)
who completed the last visit used in the analysis. For the
primary endpoint analysis, Fisher’s exact test was used to
compare responder rates between the two treatment groups
in the ITT population. Secondary endpoints were hierarchically tested in the PP population at the 6-month time
point, with each endpoint tested in succession in the order
listed above until statistical significance was not observed.
Significance for difference between treatment arms in
proportions of ODI responders and PGIC reporting was
tested using Fisher’s exact test. Changes in the mean VASback and EQ-5D-5L scores and daily opioid intake were
analyzed using a 2-group, 2-sided, Student t-test. Levene’s
test for equality of variances was used and, when appropriate, equal variances was not assumed; p values of ≤
0.05 were considered statistically significant. Independent
biostatisticians performed all analyses, which were consistent with the prespecified statistical analysis plan.

Results

Patient Disposition
Study enrollment started on September 5, 2018, and
ended on January 27, 2020, with 211 patients. Fifty-two
patients did not meet inclusion criteria; thus, 159 patients
were randomized 1:1 to either the CMM (n = 76) or 10kHz SCS (n = 83) treatment arms. Of 83 patients randomized to the SCS arm, 80 underwent trial stimulations, 74
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FIG. 1. Disposition of all enrolled patients in the study. a Concern about COVID-19 risk due to older age and multiple comorbidities. b Defined as < 50% pain relief. c Diagnosis of ruptured discs; study exit to seek surgical interventions. d Diagnosis of cervical
myelopathy and subsequent cervical spine surgery. e Patient required hip surgery. f Perceived risk due to comorbidity. I/E = inclusion/exclusion criteria; LTF = lost to follow-up; MV = missed visit; 1M = 1 month; 3M = 3 month; 6M = 6 month; 1° = primary; 2° =
secondary.

(92.5%) of whom had successful trials, and 69 patients
ultimately received permanent implants (Fig. 1). No patients in the 10-kHz SCS arm crossed over, while 86.6%
(65/75) elected to cross from CMM to 10-kHz SCS and
proceeded with the trial stimulation. The trial success
rate was 93.8% (61/65); there were 5 posttrial withdrawals, resulting in 74.7% (56/75) of the CMM arm receiving a permanent implant. The final patient completed the
12-month visit (or 6-month postcrossover visit) on June 9,
2021. A total of 125 (86.2%) of the 145 patients who proceeded to trial stimulation (the original 10-kHz SCS arm
plus patients who crossed over) received a permanent implant. Study retention was high, with 121 of 125 patients
(96.8%) remaining in the study through the 12-month
follow-up.
Patient baseline demographics and clinical characteristics are shown in Table 1. The 2 treatment groups were
similar in terms of age, sex, and race, and the mean pain

scores and time since diagnosis were, likewise, comparable in both study arms. At baseline, all patients had
CLBP and a median time since diagnosis of more than
8 years, and 97 patients (61%) had leg pain as well. A list
of pain etiologies is shown, and the breakdown of etiologies in each treatment group is similar, with degenerative
disc disease and spondylosis affecting a majority in each
group. The groups were also similar in terms of the reasons that patients were not surgical candidates, as judged
by spine surgeon evaluation prior to randomization. In
both groups, approximately 80% of patients were not acceptable surgical candidates based on presentation and
underlying pathology, and 20% of patients were nonsurgical because they declined surgery or were at moderate to
high surgical risk due to comorbidities or other clinical
conditions. It is important to note that inclusion criteria
required that every patient be evaluated by a spine surgeon
for surgical candidacy prior to randomization.
J Neurosurg Spine Volume 37 • August 2022

191

Unauthenticated | Downloaded 08/19/22 08:07 PM UTC

Kapural et al.

TABLE 1. Patient demographics and baseline clinical characteristics
Median age, yrs (range)
Sex F/M, n
Race, n (%)*
White
Black or African American
American Indian or Alaska Native
Asian
Native Hawaiian or other Pacific Islander
Other
Median time since diagnosis of CLBP, yrs (range)
VAS pain score-back
Mean (SD)
Median (range)
Baseline leg pain present†
Pain etiology, n (%)*
Degenerative disc disease
   Internal disc disruption/annular tear
Spondylosis
   Lumbar facet-mediated pain
Radiculopathy
Mild/moderate spinal stenosis
Spondylolisthesis
Sacroiliac dysfunction
Total painDETECT scores‡
Mean (SD)
Median (range)
Nonsurgical candidate reason, n (%)
Not a good surgical candidate based on presentation & underlying pathology
Candidate for surgery but declined
Not recommended due to moderate to high surgical risk related to comorbidities
or other clinical conditions (e.g., smoking, obesity, or chronic heart failure)

CMM (n = 76)

10-kHz SCS (n = 83)

58.50 (26.0–77.0)
40/36

53 (29.0–87.0)
50/33

73 (96.1)
2 (2.6)
1 (1.3)
0
0
0
8.00 (1.0–59.0)

75 (90.4)
4 (4.8)
2 (2.4)
2 (2.4)
1 (1.2)
1 (1.2)
8.50 (0.5–52.0)

7.2 (1.0)
7.2 (4.5–9.9)
45 (59.2)

7.4 (1.2)
7.6 (4.0–10.0)
52 (62.7)

52 (68.4)
6 (7.9)
49 (64.5)
25 (32.9)
35 (46.1)
24 (31.6)
9 (11.8)
5 (6.6)

60 (72.3)
8 (9.6)
55 (66.3)
24 (28.9)
34 (41.0)
23 (27.7)
7 (8.4)
3 (3.6)

17.2 (7.4)
17.5 (0.0–37.0)

17.8 (6.9)
18.0 (1.0–33.0)

61 (80.3)
10 (13.2)
5 (6.6)

65 (78.3)
11 (13.3)
6 (7.2)

* Patients may have > 1 race or pain etiology reported.
† Only patients with a left or right lower-limb baseline pain score ≥ 5.
‡ painDETECT is a patient-reported assessment of neuropathic pain. Scores range from −1 to 38, with scores ≥ 19 indicating the likelihood
(> 90% probability) that the patient has neuropathic pain.

Primary Endpoint
The results of the primary endpoint analysis are shown
in Fig. 2A. Results in the PP population showed that 55 patients (80.9%) treated with 10-kHz SCS were responders,
significantly more than the single responder (1.3%) in the
CMM group (p < 0.001). The results obtained using the
ITT analysis were similar in the CMM arm (1.3%) while
74.3% of patients in the 10-kHz SCS arm were responders
(p < 0.001).
Secondary Endpoints
Outcomes of the secondary endpoints analyzed at 6
months are summarized in Table 2, including the crossover group at 3 and 6 months postimplantation. Disability
was assessed by ODI scores, and the mean ODI score for
patients in the 10-kHz SCS treatment group decreased
192

24.2 points at the 3-month follow-up, in the range of moderate disability levels, and the mean 6-month score was
22.7 points lower than baseline. ODI scores in the control group, in contrast, did not significantly change from
baseline through 6 months. The MCID for ODI scores
used in this study is 10 points,24,25,29 and patients who had
ODI score decreases of ≥ 10 points were defined as ODI
responders. Approximately two-thirds of patients in the
treatment arm were ODI responders after 1 month of stimulation, and 78.5% were responders at 6 months (Fig. 2B).
In comparison, 4% of patients in the CMM arm were ODI
responders after 6 months.
The next secondary outcome to be tested, the mean
pain score, declined by 72% in patients who received 10kHz SCS after 6 months of treatment, yet rose 6% in those
who received CMM alone (p < 0.001). These pain relief
results were supported by other secondary outcomes, in-
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FIG. 2. Bar graphs showing a comparison between groups for the primary and secondary outcomes. A: The responder rates for
pain relief (≥ 50% reduction in the VAS score) at 3 and 6 months. B: ODI responder rates (percentage of patients with a ≥ 10-point
decrease) at 3 and 6 months. C: Distribution of patient responses on the PGIC. D: Change between baseline and 6 months in reported quality of life as measured by the EQ-5D-5L. *p < 0.001 for between-group comparison with the Fisher’s exact test. Figure
is available in color online only.

cluding reported PGIC scores, which revealed that 1.3%
of patients who received CMM perceived that their condition was “better” or “a great deal better” after 6 months
of treatment (Fig. 2C); 70.8% of patients who received
10-kHz SCS reported the same. Changes in patient quality of life, as assessed by the EQ-5D-5L index score, are
shown in Fig. 2D. Mean EQ-5D-5L scores were similar at
baseline but rose 0.20 points after 3 months of treatment
in patients who received 10-kHz stimulation, and this increase was maintained through 6 months. This change was
nearly 3 times the MCID for the index score and was significantly higher than the mean score for control patients
at 6 months.
Finally, in patients receiving opioids (52.1% of the PP
population), the mean daily intake in the 10-kHz SCS treatment group decreased on average by 45.8% at the 6-month
follow-up compared with baseline usage, while the mean
opioid intake of the control patients increased on average
by 12.1% over the same period (Fig. 3A). After 6 months
of treatment, 21.9% (7/32) of patients who received 10-kHz
stimulation had stopped taking opioid analgesics altogether

and a further 44% (14/32) of patients experienced a decrease in their daily dose, while 17.1% (7/41) of control patients experienced a decrease in their analgesic intake and
none had stopped taking opioids completely (Fig. 3B).
Individual pain relief is shown in Fig. 4. A total of 52
patients in the treatment group (80.0%) were pain responders (≥ 50% pain relief) at the 6-month follow-up, significantly more than the 2 responders in the CMM group
(2.7%). The proportion of patients who reported profound
pain relief, defined as ≥ 80% reduction in pain, was 58.5%
among patients who received SCS and 0% in the control
group. This responder rate was stable over the 12 months
of follow-up in the treatment group, with 78.2% of patients
(50/64) as responders. The responder rate at 6 months in
the crossover group was equivalent to the original treatment group at 78.2% (43/55).
The primary and secondary reported outcomes all
showed durability to the 12-month follow-up in the 10kHz SCS group (Fig. 5). The mean reported back and leg
pain scores over the 12 months of follow-up are shown in
Fig. 5A, with both sustaining a mean VAS score < 2.5 cm.
J Neurosurg Spine Volume 37 • August 2022
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TABLE 2. Secondary endpoints evaluated 3 and 6 months postbaseline for both randomized arms and crossovers
CMM
Outcome

Value

ODI responder, n (%)§
3 mos

10-kHz SCS
Total No.
of Pts

Value

Crossovers to 10-kHz SCS†

Total No.
of Pts

p
Value*

Value

Total No.
p
of Pts
Value‡

9 (12)

75

55 (80.9)

68

<0.001

42 (76.4)

55

0.0976

3 (4)

75

51 (78.5)

65

<0.001

43 (78.2)

55

0.5242

3 mos

0.41 (20.8)

75

−74.1 (25.9)

68

<0.001

−64 (33.3)

55

0.6578

6 mos

6.2 (21.7)

75

−72 (32)

65

<0.001

−70.4 (29.2)

55

0.8252

1 (1.3)

75

47 (69.1)

68

<0.001

NC

1 (1.3)

75

46 (70.8)

65

<0.001

36 (65.5)

55

0.5599

6 mos
Mean % change in VAS pain score-back (SD)

PGIC improvement (better or a great deal
better), n (%)
3 mos
6 mos

0.4469

Mean change in EQ-5D-5L score (SD)
3 mos

0.004 (0.150)

75

0.207 (0.136)

68

<0.001

0.179 (0.131)

55

0.3376

6 mos

−0.042 (0.144)

75

0.201 (0.126)

65

<0.001

0.182 (0.135)

55

0.5391

Mean change in daily opioid dose, MME (SD)
3 mos

4.9 (12.9)

41

−13.5 (30)

33

<0.001

−2.9 (39.5)

29

0.2448

6 mos

1.0 (10.8)

42

−17.7 (27.0)

32

<0.001

−5.7 (44.1)

28

0.2148

MME = milligram morphine equivalent; NC = not collected.
* Comparison between randomized groups.
† Time interval represents months postimplant for crossover group.
‡ Comparison between 10-kHz SCS arm and crossovers.
§ ODI responder is defined as those patients with ≥ 10-point reduction in ODI score compared with their baseline score.

The ODI total score remained at a 22.5 (SD 16.4) point reduction from baseline to 12 months (Fig. 5B), and the EQ5D-5L index score remained 0.20 (SD 0.15) points above
baseline (Fig. 5C), both mirroring the pain outcome. The

average percent change in opioid daily dose from baseline
is shown in Fig. 5D, which was a statistically significant
reduction at all time points (p < 0.05), with the reduction
remaining at an average 49.6% at 12 months.

FIG. 3. A: Bar graph showing the change in daily opioid dosage (milligram morphine equivalent [MME]) for both treatment groups
from baseline to 6 months of treatment. B: Bar graph showing the treatment groups broken down by the proportion of patients
increasing, decreasing, stopping, or maintaining their daily opioid dose from baseline to the 6-month follow-up; 66% of patients in
the 10-kHz SCS group had a decreased dose or stopped receiving opioids between baseline and 6 months. Figure is available in
color online only.
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FIG. 4. Individual pain relief, as measured by VAS scores, is shown with the patients having the most pain relief at the top of the
tornado plots and the patients reporting the least pain relief at the bottom. The color coding indicates the level of pain relief, with
the legend including the percentage of patients at that level of pain relief. Responder indicates ≥ 50% pain relief, and profound
responder indicates ≥ 80% pain relief. A: CMM-alone arm at 6 months. B: 10-kHz SCS treatment arm at 6 months. C: Crossover
to 10-kHz SCS cohort at 6 months postimplantation. D: Randomized 10-kHz SCS arm at 12 months. Figure is available in color
online only.

Safety Outcomes
The study-related AE occurrence in the 145 patients
who underwent trial stimulation (both the original 10-kHz
SCS arm and the crossover group) was 41 AEs, which occurred in 35 patients (24.1%), including 36 (87.8%) of 41
AEs that were either mild or moderate in severity. The
most common AE was implant site pain, reported by 7 patients (4.8%), of whom 3 (2.0%) required implantable pulse
generator (IPG) repositioning. Implant site infection was
reported by 5 patients (3.4%), and 3 patients (2.0%) had
transient CSF leakage. Five patients (3.4%) underwent lead
revisions, 3 due to lead dislodgment and 2 due to lack of
therapeutic effect.
A total of 5 study-related SAEs was reported in the
combined cohort (all patients who received an implant)
and all were procedure related (Table 3). There were 2
patients (1.4%) with infections resulting in explantation,

both of whom underwent reimplantation after the infection resolved. All SAEs resolved without sequelae. Notably, there were no explantations due to lack of therapeutic
effect. The majority of patients in both groups maintained
their neurological status on motor, sensor, and reflex assessments. There were 3 cases of a deficit in the CMM
group, motor (n = 1) and sensory (n = 2), at 3 months,
with 1 sensory deficit remaining at 6 months. One sensory deficit was reported in the 10-kHz SCS group at 3
months, which was attributed to stimulation. The stimulation was adjusted and the sensory deficit resolved. No
deficits were reported in the 10-kHz SCS arm at 6 or 12
months. Improved performance on standard neurological
assessments was observed in 16.9% of patients (n = 11)
who received 10-kHz SCS and for a single patient in the
CMM arm. Improvement was statistically significant (p
= 0.001, 2-sided Mann-Whitney U-test), and most were
J Neurosurg Spine Volume 37 • August 2022
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FIG. 5. Secondary outcome trends to 12 months in the 10-kHz SCS arm, including back and leg pain (VAS) (A), disability score
(ODI) (B), overall health score (EQ-5D-5L) (C), and percentage change in opioid daily dose (D). At the 12-month follow-up, the mean
reported VAS-back score was 2.1 ± 2.2 cm, corresponding to reduction of 72% from baseline. Figure is available in color online only.

observed in the motor assessment portion of the neurological examination.

Discussion

Results from the SENZA-RCT provide level I evidence of the safety and efficacy of 10-kHz SCS in patients
with CLBP from a variety of etiologies, including some
who were surgery naive.30 However, most patients in the

SENZA-RCT and other large prospective trials of 10-kHz
SCS in CLBP have reported a history of spine surgery
and, thus, were assigned a diagnosis of FBSS.10–13 FBSS
pain is often multifactorial due to tissue manipulation,
surgical complications, new or persistent neuropathic
pain, and/or central somatic sensitization,14 and, therefore,
may overlap with the NSRBP pain etiology. Although the
efficacy of 10-kHz SCS for treating surgery-naive back
pain has been supported by smaller prospective case se-

TABLE 3. Summary of study-related SAEs
No. of SAEs

No. of Pts w/ SAEs (%), n = 145

Implant site infection
Poor wound healing
Lethargy

2
1
1

2 (1.4)
1 (0.7)
1 (0.7)

Osteomyelitis

1

1 (0.7)

Total

5

5 (3.4)

196

Action Taken/Comments
IPGs were explanted & reimplanted when infection resolved.
Treated w/ device explant & primary closure.
Severe lethargy due to narcotic use, resulting in extended hospital stay;
symptoms resolved w/o further sequelae.
Developed osteomyelitis as a complication of the trial & did not go on to
receive a permanent implant.

J Neurosurg Spine Volume 37 • August 2022
Unauthenticated | Downloaded 08/19/22 08:07 PM UTC

Kapural et al.

ries and the outcomes of larger subcohort studies,10,11,17,31
this is the first RCT conducted in a large NSRBP patient
population.
The results presented here show profound improvements for patients with NSRBP who received 10-kHz SCS
in addition to CMM compared with those who received
CMM alone. The primary endpoint was met and strongly
favored the addition of 10-kHz SCS to CMM, as more
than 80% of patients qualified as responders with pain relief of ≥ 50%. This response rate is comparable with that
reported in large studies conducted primarily or entirely
within the FBSS patient population, including the pivotal
SENZA-RCT.10,11,15 The responder rate for the original 10kHz SCS arm and the crossover group in our study is also
similar to the 75% responder rate reported in the small
pilot study.17 Finally, our results are comparable with realworld evidence from a large retrospective study (n = 844)
in Europe and the United States that found a 12-month
responder rate of 77.6% in patients with chronic back and
leg pain,32 further demonstrating the stability of the results
across several geographic regions and different populations of patients with CLBP.
The secondary endpoints, which assessed measures of
function, quality of life, patient satisfaction, and opioid
analgesic usage, were all significantly improved with 10kHz SCS relative to CMM alone. The mean ODI score
decreased by 24.2 points after 3 months in the stimulation arm, and was 22.7 points lower after 12 months, more
than double the MCID of 10 points.24,25,29 The proportion
of patients in the 10-kHz SCS arm who had ODI score decreases exceeding 10 points (ODI responders) was 78.5%.
The mean pain intensity in patients who received SCS decreased 5.4 cm (72.0%), which is more than twofold the
MCID of 2 cm.33 Compared with previous studies in the
FBSS population, the concordance of these results in patients with NSRBP supports the comparable efficacy of
therapeutic treatment with 10-kHz SCS.
Despite no specified opioid weaning protocol, usage
in this study declined by 45.8% on average in patients
who received SCS treatment, while it increased among
patients who received CMM alone. The changes were
significant, even with the high variation in prescribed
opioid dosages across patients in both groups. Opioidsparing effects have been seen in many other studies of
10-kHz SCS.15 This is significant because opioid-related
AEs negatively impact a patient’s quality of life with little
evidence of long-term efficacy, and high doses of opioids
expose patients to the more serious risks of misuse and
overdose.34
In the current RCT, study-related AE rates were similar
to those reported in the literature, including the SENZARCT which had a study-related AE rate of 27.7%.10 The
most common related AE was IPG site pain (4.8%), comparable with 5% to 10% reported in the literature.35–37 The
3.4% infection rate is also similar to reports in the literature.36,38 There were no explantations due to loss of efficacy.
All outcomes were stable for the 12 months of followup in the 10-kHz SCS arm and patients who crossed over
to the 10-kHz SCS therapy had comparable improvements
postcrossover.

Limitations
This study is potentially limited by the lack of ability
to blind between treatment groups, which could introduce
bias into the results. However, this is a pragmatic, openlabel study that is not designed to control for patient expectations or the placebo effect since these factors are present
in the real-world treatment of NSRBP.7
Several measures have been taken to minimize potential study bias, including the participation of outside medical experts in the design of the study and the utilization of
independent physician investigators for patient selection,
data collection, and oversight of study conduct at their
respective sites. An independent statistician provided the
interim analysis and evaluation of primary and secondary
endpoints per a prespecified statistical analysis plan. In
addition, the primary endpoint was reported for the ITT
population, while secondary outcomes were reported for
the PP population. Attrition, which is the percentage of
all randomized patients (ITT group) with reported outcomes, is an important measure of the overall conduct of
any RCT, with a follow-up rate of < 80% associated with a
lower level of evidence.39,40 In this study, 94% and 92% of
the randomized patients had reported outcomes at 3 and 6
months, respectively.
These results have strong applicability to real-world
spine specialists and the pain management community
given that, other than the requirement that patients meet
the definition of NSRBP, the inclusion criteria were based
on requirements for SCS implantation in the standard
clinical setting. Also, the control treatment (CMM) represents the only currently available therapy options for patients with NSRBP. One may argue that the control group
is flawed in that CMM has already been tried and failed,
but the purpose of this study was to quantify the benefits
of adding 10-kHz SCS to the established standard of care
for these patients. The fact that CMM was not precisely
prescribed by the protocol may be considered a limitation
since it is dependent on the best practice at each site, but it
also allowed for continuation of individualized care. This
individualized care may have helped ameliorate the potential confounding effect on the patient-reported outcomes
related to potential disappointment over being randomized
to receive care they were already receiving.
The pragmatic inclusion criteria and lack of a standardized CMM therapy strengthen the external validity
of the study, for clinicians making patient care decisions
and for medical payers who do not currently reimburse
for SCS therapy in this population; hopefully, this provides evidence supporting expanded access to SCS therapy for patients with NSRBP. The SCS-implanted cohort
will be followed observationally for 24 months in order to
corroborate long-term data obtained in a small feasibility
study16 that demonstrated durable efficacy and benefit in
this population. Moreover, successful experience with salvaging failed traditional SCS implants by replacing them
with 10 kHz implants41,42 has suggested that 10-kHz SCS
may be more effective than traditional SCS in the long
term.
It bears repeating that each patient was examined and
worked up by a spinal surgeon who confirmed that they
were not candidates for direct operative intervention.
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These patients were evaluated and ruled out for spinal tumor, fracture, infection, instability, significant compressive
disease, or spondylosis amenable to surgical correction
that would likely lead to significant improvement in their
condition. Each patient had also exhausted all available
appropriate nonoperative medical management including
physical therapeutics, injection therapy, and trials of oral
medications for their intractable low-back pain. The long
interval of time between diagnosis and enrollment in the
study seen for most patients (median of approximately 8
years in treatment groups and ≥ 50 years on the high end)
demonstrates the refractory nature of their pain and the
need for safe and effective treatments.

Conclusions

The current study has demonstrated that the addition of
10-kHz SCS to CMM resulted in profound improvements
in pain relief, function, quality of life, and awareness of
positive change, as well as reduction in daily opioid use, 12
months postimplantation. The quality-of-life improvement
achieved is more than double the MCID, while maintaining a good safety profile and with the added advantage of
being a completely reversable therapy.
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